This is a pre-recorded webinar presented by Dr. Stephan T. Stern, in partnership with One Million Solutions in Health.
“This webinar demonstrated how this Polylysine Succinate (PLS) platform is superior to liposome and micellar drug delivery systems. For new therapeutics, use less drug, with less side effects and higher efficacy. For current therapeutics, this could extend your patent life. This PLS platform has the ability to replace liposome and micellar systems, and become the new Gold Standard.
This technology is directed to a polylysinesuccinate (PLS) based polymeric drug delivery platform that delivers a therapeutic cargo (e.g., small molecule drugs, therapeutic peptides, and vaccines) to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations. The PLS based delivery platform specifically targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. Unlike currently available therapeutics that target the lymphatic system through passive diffusion through porous vasculature, this novel PLS delivery platform selectively targets the lymphatic system through SR-A1 mediated transcytosis. The PLS delivery platform has superior stability and release characteristics, compared to currently available therapeutics targeting the lymphatic system, releasing the therapeutic payload in a manner that results in a superior therapeutic effect.”
For questions about the technology, please feel free to reach out to Dr. Stern at firstname.lastname@example.org.